Authors: Georges Guiella , Shani Turke, Hamadou Coulibaly, Scott Radloff, & Yoonjoung Choi
Journal: Global Health: Science and Practice, 6(1). March 2018
Researchers found evidence of a rapid uptake of the subcutaneous injectable in Burkina Faso based on data collected from Performance Monitoring and Accountability 2020 (PMA2020). PMA2020 is the first survey to track programmatic progress of the subcutaneous injectable (also referred to as SC-Injectable, or its commercial name, Sayana Press) at the population and health facility level in Burkina Faso since the method was first piloted in select regions in 2014 and introduced at the national level in 2016. Researchers at PMA2020 found that SC-Injectable prevalence in Burkina Faso almost doubled over a 6-month period, using data from the third and fourth rounds of data collection (March-May 2016 and November-January 2017, respectively). The article highlights key findings, including:
- Over the course of the two survey rounds, the availability of the SC-Injectable at public service delivery points increased from 50% to 85%, driven mainly by increases in availability in the non-pilot regions.
- Over the course of the two survey rounds, modern contraceptive use (mCPR) among all women remained comparable at 23%, but SC-Injectable prevalence nearly doubled from 1.1% to 2.0%, accounting for 9% of the modern method mix.
- Although not statistically significant, SC-injectable use was higher among rural women than their urban counterparts (2.1% vs. 1.7%), which may be attributable to the mobilization of more community health workers (CHWs) promoting the method in rural areas. In the rural areas of the pilot regions, SC-Injectable use increased from 1.8% to 3.2% over the two survey rounds.